aspirin + clopidogrel (University of Alberta)

CoPRIME is a dual antiplatelet regimen consisting of aspirin and clopidogrel. It is being evaluated as a secondary prevention strategy to reduce the risk of recurrent ischemic stroke in patients who have recently undergone acute stroke reperfusion therapies, such as intravenous thrombolysis and/or endovascular thrombectomy. Aspirin acts as an irreversible inhibitor of cyclooxygenase-1 (COX-1), preventing the synthesis of thromboxane A2, while clopidogrel is a prodrug that irreversibly blocks the P2Y12 adenosine diphosphate (ADP) receptor on platelets. Together, they provide synergistic inhibition of platelet aggregation to prevent thrombus formation. The regimen is being studied in clinical trials, including the ACT-GLOBAL adaptive platform trial, to assess its safety, feasibility, and efficacy compared to single antiplatelet therapy.